Merck has received FDA approval for Lipfendra, a new daily oral medication designed to lower LDL, or “bad” cholesterol. By providing a pill-based version of a PCSK9 inhibitor, the drug offers a therapeutic alternative to traditional statins. According to Merck, the treatment is expected to be available to patients within weeks at a list price of $10.50 per day.
The Shift from Injectable to Oral Cholesterol Treatment
Previously, this medication had to be taken as an injection. The transition to a daily pill format is intended to increase accessibility and patient adherence. Dr. Paja Banka, associate vice-president for global clinical development at Merck and a pediatric cardiologist, notes that current standard treatments are falling short for a large segment of the population.
“Seventy per cent of patients are not getting to their LDL goal,” Dr. Banka said. Clinical trials cited by The New York Times indicate that Lipfendra can reduce LDL levels to 50 or 60 mg/dL, or even lower, offering a more potent option for those who do not respond sufficiently to statins alone.
Did you know?
Heart disease remains the leading cause of death in the United States. High levels of LDL cholesterol contribute directly to atherosclerotic cardiovascular disease (ASCVD), which involves the dangerous buildup of plaque in the arteries.
Managing Side Effects and Combination Therapy
Statins remain the most widely prescribed medication for cholesterol management in the US, but they are frequently associated with muscle aches and suboptimal results. Merck’s clinical data suggests that Lipfendra may resolve some of these tolerance issues.
According to Dr. Banka, the side-effect profile for the new pill appeared minimal during trials, with no muscle aches. The drug is intended to be used in conjunction with statins for many patients, though it may be prescribed as a standalone therapy in specific cases.
Updated Cholesterol Guidelines and Risk Targets
Determining the appropriate LDL level depends on an individual’s specific cardiac history and risk factors. New guidelines issued in March by the American College of Cardiology and the American Heart Association emphasize tiered goals for patients:
- Borderline or intermediate risk: LDL-C should be less than 100 mg/dL to prevent a first heart attack or stroke.
- High risk: LDL-C goals are set at less than 70 mg/dL.
- Very high risk (ASCVD patients): Goals are set at less than 55 mg/dL for secondary prevention of cardiac events.
While the list price for the medication is set at $10.50 per day—totaling over $300 a month—Merck has indicated that actual out-of-pocket costs for many patients may be lower.
Frequently Asked Questions
How is Lipfendra different from statins?
Statins are the traditional standard for lowering cholesterol but can cause muscle pain. Lipfendra is a PCSK9 inhibitor that works differently, providing an alternative or add-on therapy that showed minimal side effects in trials.
Can I stop taking my statins once I start this new pill?
The drug is designed to be taken in conjunction with statins, though it can be used alone in some cases. Always consult your cardiologist regarding changes to your specific prescription regimen.
What are the current LDL goals for heart health?
Guidelines recommend keeping LDL levels below 100 mg/dL for most people, with stricter targets of 70 mg/dL or 55 mg/dL for those at higher risk of cardiovascular events.
Are you currently managing high cholesterol with statins? Share your experience with medication adjustments in the comments below, or subscribe to our health newsletter for the latest updates on cardiovascular research and FDA approvals.
Worth a look
